Global Monoclonal Antibodies (mAbs) Market 2020-2030

Bonafide Trust 02-02-2022 165 Pages
Region : Global Category : Lifescience Healthcare

Request new version

Request for updated version of the report at the same price

Order Now

Report Description
Table of Contents
List of Figure Tables

Global monoclonal antibodies market will reach $329.6 billion by 2030, growing by 10.9% annually over 2020-2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies. Highlighted with 83 tables and 84 figures, this 165-page report “Global Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Region. Based on Source, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Human • Humanized • Chimeric • Murine Based on Category, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Branded mAbs • Biosimilar mAbs Based on Production Type, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • In Vitro Production • In Vivo Production Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Cancer • Breast Cancer • Colorectal Cancer • Lung Cancer • Ovarian Cancer • Other Cancer Types • Autoimmune Diseases • Inflammatory Diseases • Infectious Diseases • Other Applications By End User, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospitals • Research Institutes • Other End Users Geographically, the following regions together with the listed national/local markets are fully investigated: • North America (U.S., Canada, and Mexico) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (UAE, Saudi Arabia, South Africa, Other Nations) For each aforementioned region and country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Source, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories AbbVie, Inc. Amgen Inc. AstraZeneca plc Bayer AG Bristol-Myers Squibb Company Eli Lilly F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc Johnson & Johnson Merck & Co., Inc. Mylan N.V Norvatis AG Pfizer Sanofi S.A. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 9

1.1 Industry Definition and Research Scope 9

1.1.1 Industry Definition 9

1.1.2 Research Scope 10

1.2 Research Methodology 13

1.2.1 Overview of Market Research Methodology 13

1.2.2 Market Assumption 14

1.2.3 Secondary Data 14

1.2.4 Primary Data 14

1.2.5 Data Filtration and Model Design 15

1.2.6 Market Size/Share Estimation 16

1.2.7 Research Limitations 17

1.3 Executive Summary 18

2 Market Overview and Dynamics 21

2.1 Market Size and Forecast 21

2.1.1 Impact of COVID-19 on World Economy 22

2.1.2 Impact of COVID-19 on the Market 25

2.2 Major Growth Drivers 27

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 35

2.5 Porter’s Fiver Forces Analysis 39

3 Segmentation of Global Market by Source 43

3.1 Market Overview by Source 43

3.2 Human 45

3.3 Humanized 46

3.4 Chimeric 47

3.5 Murine 48

4 Segmentation of Global Market by Category 49

4.1 Market Overview by Category 49

4.2 Branded mAbs 51

4.3 Biosimilar mAbs 52

5 Segmentation of Global Market by Production Type 53

5.1 Market Overview by Production Type 53

5.2 In Vitro Production 55

5.3 In Vivo Production 56

6 Segmentation of Global Market by Application 57

6.1 Market Overview by Application 57

6.2 Cancer 59

6.2.1 Breast Cancer 61

6.2.2 Colorectal Cancer 62

6.2.3 Lung Cancer 63

6.2.4 Ovarian Cancer 64

6.2.5 Other Cancer Types 65

6.3 Autoimmune Diseases 66

6.4 Inflammatory Diseases 67

6.5 Infectious Diseases 68

6.6 Other Applications 69

7 Segmentation of Global Market by End User 70

7.1 Market Overview by End User 70

7.2 Hospitals 72

7.3 Research Institutes 73

7.4 Other End Users 74

8 Segmentation of Global Market by Region 75

8.1 Geographic Market Overview 2019-2030 75

8.2 North America Market 2019-2030 by Country 79

8.2.1 Overview of North America Market 79

8.2.2 U.S. 83

8.2.3 Canada 86

8.2.4 Mexico 88

8.3 European Market 2019-2030 by Country 90

8.3.1 Overview of European Market 90

8.3.2 Germany 94

8.3.3 U.K. 96

8.3.4 France 98

8.3.5 Spain 100

8.3.6 Italy 102

8.3.7 Russia 104

8.3.8 Rest of European Market 106

8.4 Asia-Pacific Market 2019-2030 by Country 108

8.4.1 Overview of Asia-Pacific Market 108

8.4.2 Japan 112

8.4.3 China 115

8.4.4 Australia 117

8.4.5 India 119

8.4.6 South Korea 121

8.4.7 Rest of APAC Region 123

8.5 South America Market 2019-2030 by Country 125

8.5.1 Argentina 128

8.5.2 Brazil 130

8.5.3 Chile 132

8.5.4 Rest of South America Market 134

8.6 MEA Market 2019-2030 by Country 135

8.6.1 UAE 138

8.6.2 Saudi Arabia 140

8.6.3 South Africa 142

8.6.4 Other National Markets 144

9 Competitive Landscape 145

9.1 Overview of Key Vendors 145

9.2 New Product Launch, Partnership, Investment, and M&A 148

9.3 Company Profiles 149

Abbott Laboratories 149

AbbVie, Inc. 151

Amgen Inc. 152

AstraZeneca plc 153

Bayer AG 154

Bristol-Myers Squibb Company 155

Eli Lilly 156

F. Hoffmann-La Roche Ltd. 157

GlaxoSmithKline Plc 158

Johnson & Johnson 159

Merck & Co., Inc. 160

Mylan N.V 161

Norvatis AG 162

Pfizer 163

Sanofi S.A. 164

RELATED REPORTS 165

List of Figures:

Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 18
Figure 4. Global Monoclonal Antibodies Market, 2019-2030, $ bn 21
Figure 5. Impact of COVID-19 on Business 25
Figure 6. Primary Drivers and Impact Factors of Global Monoclonal Antibodies Market 27
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 30
Figure 9. Primary Restraints and Impact Factors of Global Monoclonal Antibodies Market 32
Figure 10. Investment Opportunity Analysis 36
Figure 11. Porter’s Fiver Forces Analysis of Global Monoclonal Antibodies Market 39
Figure 12. Breakdown of Global Monoclonal Antibodies Market by Source, 2019-2030, % of Revenue 44
Figure 13. Global Addressable Market Cap in 2021-2030 by Source, Value ($ bn) and Share (%) 44
Figure 14. Global Monoclonal Antibodies Market by Source: Human, 2019-2030, $ bn 45
Figure 15. Global Monoclonal Antibodies Market by Source: Humanized, 2019-2030, $ bn 46
Figure 16. Global Monoclonal Antibodies Market by Source: Chimeric, 2019-2030, $ bn 47
Figure 17. Global Monoclonal Antibodies Market by Source: Murine, 2019-2030, $ bn 48
Figure 18. Breakdown of Global Monoclonal Antibodies Market by Category, 2019-2030, % of Sales Revenue 50
Figure 19. Global Addressable Market Cap in 2021-2030 by Category, Value ($ bn) and Share (%) 50
Figure 20. Global Monoclonal Antibodies Market by Category: Branded mAbs, 2019-2030, $ bn 51
Figure 21. Global Monoclonal Antibodies Market by Category: Biosimilar mAbs, 2019-2030, $ bn 52
Figure 22. Breakdown of Global Monoclonal Antibodies Market by Production Type, 2019-2030, % of Sales Revenue 54
Figure 23. Global Addressable Market Cap in 2021-2030 by Production Type, Value ($ bn) and Share (%) 54
Figure 24. Global Monoclonal Antibodies Market by Production Type: In Vitro Production, 2019-2030, $ bn 55
Figure 25. Global Monoclonal Antibodies Market by Production Type: In Vivo Production, 2019-2030, $ bn 56
Figure 26. Breakdown of Global Monoclonal Antibodies Market by Application, 2019-2030, % of Revenue 58
Figure 27. Global Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%) 58
Figure 28. Global Monoclonal Antibodies Market by Application: Cancer, 2019-2030, $ bn 59
Figure 29. Global Monoclonal Antibodies Market by Cancer Type: Breast Cancer, 2019-2030, $ bn 61
Figure 30. Global Monoclonal Antibodies Market by Cancer Type: Colorectal Cancer, 2019-2030, $ bn 62
Figure 31. Global Monoclonal Antibodies Market by Cancer Type: Lung Cancer, 2019-2030, $ bn 63
Figure 32. Global Monoclonal Antibodies Market by Cancer Type: Ovarian Cancer, 2019-2030, $ bn 64
Figure 33. Global Monoclonal Antibodies Market by Cancer Type: Other Cancer Types, 2019-2030, $ bn 65
Figure 34. Global Monoclonal Antibodies Market by Application: Autoimmune Diseases, 2019-2030, $ bn 66
Figure 35. Global Monoclonal Antibodies Market by Application: Inflammatory Diseases, 2019-2030, $ bn 67
Figure 36. Global Monoclonal Antibodies Market by Application: Infectious Diseases, 2019-2030, $ bn 68
Figure 37. Global Monoclonal Antibodies Market by Application: Other Applications, 2019-2030, $ bn 69
Figure 38. Breakdown of Global Monoclonal Antibodies Market by End User, 2019-2030, % of Revenue 71
Figure 39. Global Addressable Market Cap in 2021-2030 by End User, Value ($ bn) and Share (%) 71
Figure 40. Global Monoclonal Antibodies Market by End User: Hospitals, 2019-2030, $ bn 72
Figure 41. Global Monoclonal Antibodies Market by End User: Research Institutes, 2019-2030, $ bn 73
Figure 42. Global Monoclonal Antibodies Market by End User: Other End Users, 2019-2030, $ bn 74
Figure 43. Global Market Snapshot by Region 75
Figure 44. Geographic Spread of Worldwide Monoclonal Antibodies Market, 2019-2030, % of Sales Revenue 76
Figure 45. Global Addressable Market Cap in 2021-2030 by Region, Value ($ bn) and Share (%) 77
Figure 46. North American Monoclonal Antibodies Market, 2019-2030, $ bn 80
Figure 47. Breakdown of North America Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue 81
Figure 48. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 82
Figure 49. U.S. Monoclonal Antibodies Market, 2019-2030, $ bn 84
Figure 50. Canada Monoclonal Antibodies Market, 2019-2030, $ bn 86
Figure 51. Monoclonal Antibodies Market in Mexico, 2019-2030, $ bn 88
Figure 52. European Monoclonal Antibodies Market, 2019-2030, $ bn 91
Figure 53. Breakdown of European Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue 92
Figure 54. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 93
Figure 55. Monoclonal Antibodies Market in Germany, 2019-2030, $ bn 94
Figure 56. Monoclonal Antibodies Market in U.K., 2019-2030, $ bn 96
Figure 57. Monoclonal Antibodies Market in France, 2019-2030, $ bn 98
Figure 58. Monoclonal Antibodies Market in Spain, 2019-2030, $ bn 100
Figure 59. Monoclonal Antibodies Market in Italy, 2019-2030, $ bn 102
Figure 60. Monoclonal Antibodies Market in Russia, 2019-2030, $ bn 104
Figure 61. Monoclonal Antibodies Market in Rest of Europe, 2019-2030, $ bn 106
Figure 62. Asia-Pacific Monoclonal Antibodies Market, 2019-2030, $ bn 109
Figure 63. Breakdown of APAC Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue 109
Figure 64. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 111
Figure 65. Monoclonal Antibodies Market in Japan, 2019-2030, $ bn 113
Figure 66. Monoclonal Antibodies Market in China, 2019-2030, $ bn 115
Figure 67. Monoclonal Antibodies Market in Australia, 2019-2030, $ bn 117
Figure 68. Monoclonal Antibodies Market in India, 2019-2030, $ bn 119
Figure 69. Monoclonal Antibodies Market in South Korea, 2019-2030, $ bn 121
Figure 70. Monoclonal Antibodies Market in Rest of APAC, 2019-2030, $ bn 123
Figure 71. South America Monoclonal Antibodies Market, 2019-2030, $ bn 126
Figure 72. Breakdown of South America Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue 126
Figure 73. Contribution to South America 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 127
Figure 74. Monoclonal Antibodies Market in Argentina, 2019-2030, $ bn 128
Figure 75. Monoclonal Antibodies Market in Brazil, 2019-2030, $ bn 130
Figure 76. Monoclonal Antibodies Market in Chile, 2019-2030, $ bn 132
Figure 77. Monoclonal Antibodies Market in Rest of South America, 2019-2030, $ bn 134
Figure 78. Monoclonal Antibodies Market in Middle East and Africa (MEA), 2019-2030, $ bn 136
Figure 79. Breakdown of MEA Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue 136
Figure 80. Contribution to MEA 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 137
Figure 81. Monoclonal Antibodies Market in UAE, 2019-2030, $ bn 138
Figure 82. Monoclonal Antibodies Market in Saudi Arabia, 2019-2030, $ bn 140
Figure 83. Monoclonal Antibodies Market in South Africa, 2019-2030, $ bn 142
Figure 84. Growth Stage of Global Monoclonal Antibodies Industry over the Forecast Period 145

List of Tables:

Table 1. Snapshot of Global Monoclonal Antibodies Market in Balanced Perspective, 2019-2030 19
Table 2. Growth Rate of World GDP, 2020-2022 23
Table 3. World Health Spending by Region, $ bn, 2013-2020 31
Table 4. Main Product Trends and Market Opportunities in Global Monoclonal Antibodies Market 35
Table 5. Global Monoclonal Antibodies Market by Source, 2019-2030, $ bn 43
Table 6. Global Monoclonal Antibodies Market by Category, 2019-2030, $ bn 49
Table 7. Global Monoclonal Antibodies Market by Production Type, 2019-2030, $ bn 53
Table 8. Global Monoclonal Antibodies Market by Application, 2019-2030, $ bn 57
Table 9. Global Monoclonal Antibodies Market: Cancer Therapy by Type, 2019-2030, $ bn 60
Table 10. Global Monoclonal Antibodies Market by End User, 2019-2030, $ bn 70
Table 11. Global Monoclonal Antibodies Market by Region, 2019-2030, $ bn 76
Table 12. Leading National Monoclonal Antibodies Market, 2019 and 2030F, $ bn 78
Table 13. North America Monoclonal Antibodies Market by Country, 2019-2030, $ bn 81
Table 14. U.S. Monoclonal Antibodies Market by Source, 2019-2030, $ bn 85
Table 15. U.S. Monoclonal Antibodies Market by Application, 2019-2030, $ bn 85
Table 16. U.S. Monoclonal Antibodies Market by End User, 2019-2030, $ bn 85
Table 17. Canada Monoclonal Antibodies Market by Source, 2019-2030, $ bn 87
Table 18. Canada Monoclonal Antibodies Market by Application, 2019-2030, $ bn 87
Table 19. Canada Monoclonal Antibodies Market by End User, 2019-2030, $ bn 87
Table 20. Mexico Monoclonal Antibodies Market by Source, 2019-2030, $ bn 89
Table 21. Mexico Monoclonal Antibodies Market by Application, 2019-2030, $ bn 89
Table 22. Mexico Monoclonal Antibodies Market by End User, 2019-2030, $ bn 89
Table 23. Europe Monoclonal Antibodies Market by Country, 2019-2030, $ bn 93
Table 24. Germany Monoclonal Antibodies Market by Source, 2019-2030, $ bn 95
Table 25. Germany Monoclonal Antibodies Market by Application, 2019-2030, $ bn 95
Table 26. Germany Monoclonal Antibodies Market by End User, 2019-2030, $ bn 95
Table 27. U.K. Monoclonal Antibodies Market by Source, 2019-2030, $ bn 97
Table 28. U.K. Monoclonal Antibodies Market by Application, 2019-2030, $ bn 97
Table 29. U.K. Monoclonal Antibodies Market by End User, 2019-2030, $ bn 97
Table 30. France Monoclonal Antibodies Market by Source, 2019-2030, $ bn 99
Table 31. France Monoclonal Antibodies Market by Application, 2019-2030, $ bn 99
Table 32. France Monoclonal Antibodies Market by End User, 2019-2030, $ bn 99
Table 33. Spain Monoclonal Antibodies Market by Source, 2019-2030, $ bn 101
Table 34. Spain Monoclonal Antibodies Market by Application, 2019-2030, $ bn 101
Table 35. Spain Monoclonal Antibodies Market by End User, 2019-2030, $ bn 101
Table 36. Italy Monoclonal Antibodies Market by Source, 2019-2030, $ bn 103
Table 37. Italy Monoclonal Antibodies Market by Application, 2019-2030, $ bn 103
Table 38. Italy Monoclonal Antibodies Market by End User, 2019-2030, $ bn 103
Table 39. Russia Monoclonal Antibodies Market by Source, 2019-2030, $ bn 105
Table 40. Russia Monoclonal Antibodies Market by Application, 2019-2030, $ bn 105
Table 41. Russia Monoclonal Antibodies Market by End User, 2019-2030, $ bn 105
Table 42. Monoclonal Antibodies Market in Rest of Europe by Country, 2019-2030, $ bn 107
Table 43. APAC Monoclonal Antibodies Market by Country, 2019-2030, $ bn 110
Table 44. Japan Monoclonal Antibodies Market by Source, 2019-2030, $ bn 114
Table 45. Japan Monoclonal Antibodies Market by Application, 2019-2030, $ bn 114
Table 46. Japan Monoclonal Antibodies Market by End User, 2019-2030, $ bn 114
Table 47. China Monoclonal Antibodies Market by Source, 2019-2030, $ bn 116
Table 48. China Monoclonal Antibodies Market by Application, 2019-2030, $ bn 116
Table 49. China Monoclonal Antibodies Market by End User, 2019-2030, $ bn 116
Table 50. Australia Monoclonal Antibodies Market by Source, 2019-2030, $ bn 118
Table 51. Australia Monoclonal Antibodies Market by Application, 2019-2030, $ bn 118
Table 52. Australia Monoclonal Antibodies Market by End User, 2019-2030, $ bn 118
Table 53. India Monoclonal Antibodies Market by Source, 2019-2030, $ bn 120
Table 54. India Monoclonal Antibodies Market by Application, 2019-2030, $ bn 120
Table 55. India Monoclonal Antibodies Market by End User, 2019-2030, $ bn 120
Table 56. South Korea Monoclonal Antibodies Market by Source, 2019-2030, $ bn 122
Table 57. South Korea Monoclonal Antibodies Market by Application, 2019-2030, $ bn 122
Table 58. South Korea Monoclonal Antibodies Market by End User, 2019-2030, $ bn 122
Table 59. Monoclonal Antibodies Market in Rest of APAC by Country/Region, 2019-2030, $ bn 124
Table 60. South America Monoclonal Antibodies Market by Country, 2019-2030, $ bn 127
Table 61. Argentina Monoclonal Antibodies Market by Source, 2019-2030, $ bn 129
Table 62. Argentina Monoclonal Antibodies Market by Application, 2019-2030, $ bn 129
Table 63. Argentina Monoclonal Antibodies Market by End User, 2019-2030, $ bn 129
Table 64. Brazil Monoclonal Antibodies Market by Source, 2019-2030, $ bn 131
Table 65. Brazil Monoclonal Antibodies Market by Application, 2019-2030, $ bn 131
Table 66. Brazil Monoclonal Antibodies Market by End User, 2019-2030, $ bn 131
Table 67. Chile Monoclonal Antibodies Market by Source, 2019-2030, $ bn 133
Table 68. Chile Monoclonal Antibodies Market by Application, 2019-2030, $ bn 133
Table 69. Chile Monoclonal Antibodies Market by End User, 2019-2030, $ bn 133
Table 70. MEA Monoclonal Antibodies Market by Country, 2019-2030, $ bn 137
Table 71. UAE Monoclonal Antibodies Market by Source, 2019-2030, $ bn 139
Table 72. UAE Monoclonal Antibodies Market by Application, 2019-2030, $ bn 139
Table 73. UAE Monoclonal Antibodies Market by End User, 2019-2030, $ bn 139
Table 74. Saudi Arabia Monoclonal Antibodies Market by Source, 2019-2030, $ bn 141
Table 75. Saudi Arabia Monoclonal Antibodies Market by Application, 2019-2030, $ bn 141
Table 76. Saudi Arabia Monoclonal Antibodies Market by End User, 2019-2030, $ bn 141
Table 77. South Africa Monoclonal Antibodies Market by Source, 2019-2030, $ bn 143
Table 78. South Africa Monoclonal Antibodies Market by Application, 2019-2030, $ bn 143
Table 79. South Africa Monoclonal Antibodies Market by End User, 2019-2030, $ bn 143
Table 80. Abbott Laboratories: Company Snapshot 149
Table 81. Abbott Laboratories: Business Segmentation 149
Table 82. Abbott Laboratories: Product Portfolio 150
Table 83. Abbott Laboratories: Revenue, 2018-2020, $ bn 150

Interested in this report?
Get your FREE sample!

Safe and Secure SSl Encryption

Licensing options

3200
USD

Single User License
Site License
Global User License

How client has rates us?

Requirement Gathering & Methodology

Data Collection Techniques

Our Research Team & Data Sourcing

Data Science & Analytical Tools

Data Visualization & Presentation Skills

Project/ Report Delivery & After Sales Services

Testimonial

READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.

PRODUCT DEVELOPMENT MANAGER

CEO

Vivek Arora

BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!

EXECUTIVE DIRECTOR

Rahul Roy

THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.

SALES DIRECTOR

Arjun Prasad

THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH

MARKETING MANAGER

President

Manish Verma

Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

MARKETING DIRECTOR

Gautam Saxena

The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.

PRODUCT MANAGER

Tom Stone

I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.

Associate Director

Mark Wood

Global Monoclonal Antibodies (mAbs) Market 2020-2030

Global Monoclonal Antibodies (mAbs) Market 2020-2030